Novartis Launches Direct-to-Patient Platform for Cosentyx in U.S.

The platform will enable cash-paying patients prescribed Cosentyx (secukinumab) to access the medicine at a 55% discount off the list price.

Novartis announced that it will launch a direct-to-patient (DTP) platform in the United States starting November 1, 2025. 

The platform will enable cash-paying patients prescribed Cosentyx (secukinumab) to access the medicine at a 55% discount off the list price.

Cosentyx is a biologic therapy approved by the U.S. Food and Drug Administration (FDA) for treating multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa, and psoriatic arthritis. Since its 2015 launch, Cosentyx has been prescribed to more than 1.8 million patients globally and is supported by over 17 years of clinical research.

Victor Bultó, President of Novartis US, stated, “Breakthrough innovation is what drives us at Novartis—whether in scientific research, medicine development, or the ways we deliver our therapies to patients. We recognize the need for new approaches to reach patients more directly by removing barriers in the system. The launch of this platform is an important first step in offering our net prices more directly to patients and working toward a healthcare system that better serves Americans.”

Through the new DTP platform, Novartis aims to provide Cosentyx at a price reflecting the average savings typically retained by insurers and pharmacy benefit managers. The initiative serves as a proof-of-concept for a direct-selling model in specialty medicines, designed to complement insurance coverage and improve affordability.

Novartis also plans to expand the DTP approach to additional products in its portfolio where appropriate. The company is exploring a direct-to-employer model to provide Cosentyx and potentially other medicines directly to large employers, to increase access and affordability for U.S. patients.

Stay tuned for more such updates on Digital Health News